å¥½çš„ï¼æˆ‘ä»¬å¯ä»¥æŒ‰ç…§ä½ æä¾›çš„ **Reverse Outline Instructions**ï¼ˆåå‘å¤§çº²æ­¥éª¤ï¼‰å¯¹è¿™ç¯‡æ–‡ç« è¿›è¡Œ**ç³»ç»Ÿåˆ†æå’Œæ”¹å†™**ã€‚æˆ‘å°†åˆ†ä¸ºä»¥ä¸‹å‡ ä¸ªé˜¶æ®µå±•ç¤ºè¿‡ç¨‹ï¼š

---

## ğŸ§© Step 1. æ®µè½ç¼–å·

åŸæ–‡å…± **6 æ®µ**ï¼š

1ï¸âƒ£ æ®µè½ 1ï¼šå…³äºç‰™å‘¨ç—…ä¸å¿ƒè¡€ç®¡ç–¾ç—…å…³ç³»çš„æ€»ä½“ç ”ç©¶èƒŒæ™¯ã€‚
2ï¸âƒ£ æ®µè½ 2ï¼šç‰™å‘¨ç—…çš„å®šä¹‰ä¸æµè¡Œæƒ…å†µã€‚
3ï¸âƒ£ æ®µè½ 3ï¼šç‰™å‘¨ç—…å½±å“å¿ƒè¡€ç®¡ç³»ç»Ÿçš„å¯èƒ½æœºåˆ¶ã€‚
4ï¸âƒ£ æ®µè½ 4ï¼šç ”ç©¶ç»“æœå­˜åœ¨çŸ›ç›¾ï¼Œä¸€äº›ç ”ç©¶æ”¯æŒå…³è”ï¼Œä¸€äº›ä¸æ”¯æŒã€‚
5ï¸âƒ£ æ®µè½ 5ï¼šäº‰è®®çš„åŸå› ä¸ç ”ç©¶å±€é™æ€§ã€‚
6ï¸âƒ£ æ®µè½ 6ï¼šæœ¬æ–‡ç ”ç©¶ç›®æ ‡ä¸å‡è®¾ã€‚

---

## ğŸ§© Step 2. åˆ†ææ¯ä¸ªæ®µè½

| æ®µè½ | ä¸»é¢˜å¥æ˜¯å¦æ˜ç¡® | æ®µè½ä¸»æ—¨                  | å‘å±•æ˜¯å¦å……åˆ†      | æ˜¯å¦å¤šä¸»é¢˜ |
| -- | ------- | --------------------- | ----------- | ----- |
| 1  | âœ… æ˜¯     | æå‡ºç‰™å‘¨ç—…å¯èƒ½ä¸AMIã€CHDã€CVDç›¸å…³ | è¾ƒç®€çŸ­ï¼Œä½†èµ·åˆ°å¼•å…¥ä½œç”¨ | å¦     |
| 2  | âœ… æ˜¯     | å®šä¹‰ç‰™å‘¨ç—…å¹¶è¯´æ˜å…¶æµè¡Œç¨‹åº¦         | å……åˆ†          | å¦     |
| 3  | âœ… æ˜¯     | é˜è¿°ç‰™å‘¨ç—…å¯èƒ½å½±å“å¿ƒè¡€ç®¡ç³»ç»Ÿçš„ç”Ÿç‰©æœºåˆ¶   | å……åˆ†          | å¦     |
| 4  | âœ… æ˜¯     | ç ”ç©¶ç»“æœä¸ä¸€è‡´               | ä¸­ç­‰          | å¦     |
| 5  | âœ… æ˜¯     | åˆ†æäº‰è®®åŸå› ï¼Œå¦‚æ ·æœ¬åå·®ã€ç ”ç©¶æ–¹æ³•ä¸åŒ   | å……åˆ†          | å¦     |
| 6  | âœ… æ˜¯     | é˜è¿°æœ¬æ–‡ç ”ç©¶è®¾è®¡ä¸å‡è®¾           | å……åˆ†          | å¦     |

---

## ğŸ§© Step 3. åˆæ­¥å¤§çº²ï¼ˆæ ¹æ®åŸæ–‡ï¼‰

1. **Introduction / Background**

   * ç‰™å‘¨ç—…å¯èƒ½ä¸å¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆAMIã€CHDã€CVDï¼‰æœ‰å…³ã€‚

2. **Definition and Prevalence**

   * ç‰™å‘¨ç—…æ˜¯ä¸€ç§æ…¢æ€§ç‚ç—‡æ€§ç–¾ç—…ï¼Œåœ¨æˆäººä¸­æä¸ºæ™®éã€‚

3. **Mechanisms**

   * ç‰™å‘¨ç—…çš„ç—…åŸä½“ä¸ç‚ç—‡å› å­å¯èƒ½ä¿ƒè¿›è¡€å°æ¿èšé›†ä¸åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ã€‚

4. **Inconsistent Evidence**

   * ä¸€äº›ç ”ç©¶å‘ç°ç›¸å…³æ€§ï¼Œä½†ä¹Ÿæœ‰ç ”ç©¶æœªå‘ç°æ­¤å…³è”ã€‚

5. **Limitations of Previous Studies**

   * æ ·æœ¬é‡å°ã€ç ”ç©¶äººç¾¤åå‘è€å¹´ç”·æ€§ã€æµ‹é‡æ ‡å‡†ä¸ç»Ÿä¸€ã€‚

6. **Study Purpose and Hypothesis**

   * æœ¬ç ”ç©¶æ—¨åœ¨ä½¿ç”¨æ›´å…¨é¢çš„æµ‹é‡æ–¹æ³•å’Œå¤§æ ·æœ¬ï¼ŒéªŒè¯ç‰™å‘¨ç—…ä¸AMIçš„å…³ç³»ã€‚

---

## ğŸ§© Step 4. åˆ†æé€»è¾‘ä¸ç¯‡å¹…æ¯”ä¾‹

* **é€»è¾‘é¡ºåºè‰¯å¥½**ï¼šèƒŒæ™¯ â†’ å®šä¹‰ â†’ æœºåˆ¶ â†’ äº‰è®® â†’ å±€é™æ€§ â†’ æœ¬ç ”ç©¶ç›®æ ‡ã€‚
* **ç¯‡å¹…æ¯”ä¾‹ç¨æœ‰é—®é¢˜**ï¼š

  * å‰ä¸‰æ®µè¿‡äºç®€çŸ­ï¼ˆä»…å¼•å…¥ï¼‰ï¼Œè€Œæœ€åä¸€æ®µè¿‡é•¿ï¼ˆç ”ç©¶è®¾è®¡ç»†èŠ‚å¤ªå¤šï¼‰ã€‚
  * å¯ä»¥åœ¨é€»è¾‘ä¸Šæ•´åˆç¬¬ 4ã€5 æ®µï¼ˆéƒ½åœ¨è®²ç ”ç©¶å·®å¼‚åŸå› ï¼‰ã€‚

---

## ğŸ§© Step 5. ä¿®è®¢åå¤§çº²ï¼ˆä¼˜åŒ–é€»è¾‘ä¸æ¯”ä¾‹ï¼‰

1. **Introduction:**
   æ¦‚è¿°ç‰™å‘¨ç—…ä¸å¿ƒè¡€ç®¡ç–¾ç—…æ½œåœ¨å…³è”çš„é‡è¦æ€§ã€‚

2. **Background on Periodontal Disease:**
   å®šä¹‰ã€æµè¡Œæƒ…å†µï¼Œä»¥åŠå…¶æ…¢æ€§ç‚ç—‡ç‰¹å¾ã€‚

3. **Possible Biological Mechanisms:**
   ç»†èŒã€å†…æ¯’ç´ ã€ç‚ç—‡ä»‹è´¨å¦‚ä½•å¯¼è‡´è¡€ç®¡ç—…å˜ã€‚

4. **Evidence and Controversy:**
   æ¦‚è¿°å·²æœ‰ç ”ç©¶çš„æ”¯æŒä¸å¦å®šç»“æœï¼Œå¹¶åˆ†æåŸå› ï¼ˆæ ·æœ¬ã€æµ‹é‡ã€åå·®ï¼‰ã€‚

5. **Research Purpose and Hypothesis:**
   é˜æ˜æœ¬ç ”ç©¶å°†å¦‚ä½•æ”¹è¿›æ–¹æ³•ï¼Œæå‡ºå‡è®¾ä¸ç›®æ ‡ã€‚

---

## ğŸ§© Step 6. ä¾æ®æ–°å¤§çº²é‡æ–°ç»„ç»‡æ–‡ç« ï¼ˆæ”¹å†™ç¨¿ï¼‰

---

### **Revised Version**

Over recent decades, increasing evidence has suggested that periodontal disease may be associated with an elevated risk of acute myocardial infarction (AMI), coronary heart disease (CHD), and other cardiovascular diseases (CVD). Several epidemiological studies have indicated a possible link between periodontal disease and an increased risk of AMI in men.

Periodontal disease is a chronic infectious and inflammatory condition that gradually destroys the supporting bone of teeth. It is one of the most common chronic diseases, affecting up to 75% of adults over the age of 30. The widespread prevalence and chronic nature of this condition make it a potential contributor to systemic inflammation.

Several biological mechanisms have been proposed to explain this potential association. Periodontal pathogens, endotoxins, and inflammatory mediators present in the oral cavity and bloodstream may promote platelet aggregation and the formation of atherosclerotic plaques in coronary arteries. Consequently, individuals with heightened inflammatory responses to periodontal infection could be at greater risk for developing myocardial infarction.

Despite the growing number of studies, the evidence remains inconclusive. While some research supports a significant association between periodontal disease and CHD even after adjusting for confounding factors, other studies have found no such relationship. This inconsistency may be attributed to methodological limitations, including small or selective samples, age bias toward older men, and varying definitions or measurement techniques for periodontal disease. Many prior studies relied on self-reported or indirect measures rather than direct clinical assessments or bacterial testing.

To address these limitations, the present study aims to use a population-based sample of men aged 35â€“69 years in Ontario to examine the association between periodontal disease and the incidence of first acute myocardial infarction. The study will employ comprehensive clinical assessmentsâ€”including blood cultures, IgG antibody testing, and standardized dental examinationsâ€”to determine whether the severity of periodontal disease increases AMI risk. The central hypothesis is that periodontal disease contributes to a higher risk of subsequent myocardial infarction among middle-aged men with no prior history of CHD, stroke, transient ischemic attack, or cancer.

---

âœ… **æ”¹å†™åçš„ä¼˜ç‚¹ï¼š**

* å„æ®µä¸»é¢˜æ¸…æ™°ä¸”è¿è´¯ï¼›
* åˆ é™¤å†—ä½™å¼•ç”¨å’Œæ‹¬å·ï¼›
* åˆå¹¶ç›¸ä¼¼æ®µè½ï¼Œæ¯”ä¾‹æ›´å‡è¡¡ï¼›
* æ¯æ®µä»¥ä¸»é¢˜å¥å¼€å¤´ï¼Œé€»è¾‘é€’è¿›æ˜ç¡®ï¼›
* æœ€åä¸€æ®µé‡ç‚¹çªå‡ºç ”ç©¶æ„ä¹‰ä¸å‡è®¾ã€‚

---

æ˜¯å¦å¸Œæœ›æˆ‘å¸®ä½ æŠŠè¿™ç¯‡æ”¹å†™ç‰ˆå†æ ¼å¼åŒ–æˆç¬¦åˆå­¦æœ¯è®ºæ–‡é£æ ¼ï¼ˆä¾‹å¦‚APAé£æ ¼å¼•æ–‡ã€æ­£å¼è¯­æ°”ã€é€»è¾‘è¿‡æ¸¡æ›´è‡ªç„¶ï¼‰ï¼Ÿ
